Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a

Results of cancer and leukemia group B 159904

Robert A. Kratzke, Xiaofei Wang, Long Wong, Marian G. Kratzke, Mark R. Green, Everett E. Vokes, Nicholas J. Vogelzang, Hedy L. Kindler, Jeffrey A. Kern

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

INTRODUCTION: The molecular mechanisms of oncogenesis in mesothelioma involve the loss of negative regulators of cell growth including p16. Absence of expression of the p16 gene product is exhibited in virtually all mesothelioma tumors and cell lines examined to date. Loss of p16 expression has also been frequently observed in more common neoplasms such as lung cancer as well. In a wide variety of these malignancies, including lung cancer, p16 expression is known to be inactivated by hypermethylation of the first exon. This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16 via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC). METHODS: Using tissue samples from CALGB 8833 and 9031, two clinical studies which used DHAC based therapy in mesothelioma, this study tested the hypothesis that tumors possessing methylation of p16 would have a better response and survival following DHAC treatment than their nonmethylated counterparts. RESULTS: Methylation of p16 was identified in 4 of the 20 specimens. Although there was a trend towards improved survival the result was not statistically significant. CONCLUSIONS: There was no significant correlation between the presence of p16 methylation and response to DHAC therapy or overall survival.

Original languageEnglish
Pages (from-to)417-421
Number of pages5
JournalJournal of Thoracic Oncology
Volume3
Issue number4
DOIs
StatePublished - 1 Jan 2008

Fingerprint

5,6-dihydro-5-azacytidine
Mesothelioma
Methylation
Leukemia
Neoplasms
Lung Neoplasms
p16 Genes
Cytidine
Tumor Cell Line
Exons
Carcinogenesis

Keywords

  • Mesothelioma
  • Methylation
  • p16

Cite this

Kratzke, Robert A. ; Wang, Xiaofei ; Wong, Long ; Kratzke, Marian G. ; Green, Mark R. ; Vokes, Everett E. ; Vogelzang, Nicholas J. ; Kindler, Hedy L. ; Kern, Jeffrey A. / Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a : Results of cancer and leukemia group B 159904. In: Journal of Thoracic Oncology. 2008 ; Vol. 3, No. 4. pp. 417-421.
@article{bcf072fa527b490aa2dd51d0376de331,
title = "Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: Results of cancer and leukemia group B 159904",
abstract = "INTRODUCTION: The molecular mechanisms of oncogenesis in mesothelioma involve the loss of negative regulators of cell growth including p16. Absence of expression of the p16 gene product is exhibited in virtually all mesothelioma tumors and cell lines examined to date. Loss of p16 expression has also been frequently observed in more common neoplasms such as lung cancer as well. In a wide variety of these malignancies, including lung cancer, p16 expression is known to be inactivated by hypermethylation of the first exon. This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16 via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC). METHODS: Using tissue samples from CALGB 8833 and 9031, two clinical studies which used DHAC based therapy in mesothelioma, this study tested the hypothesis that tumors possessing methylation of p16 would have a better response and survival following DHAC treatment than their nonmethylated counterparts. RESULTS: Methylation of p16 was identified in 4 of the 20 specimens. Although there was a trend towards improved survival the result was not statistically significant. CONCLUSIONS: There was no significant correlation between the presence of p16 methylation and response to DHAC therapy or overall survival.",
keywords = "Mesothelioma, Methylation, p16",
author = "Kratzke, {Robert A.} and Xiaofei Wang and Long Wong and Kratzke, {Marian G.} and Green, {Mark R.} and Vokes, {Everett E.} and Vogelzang, {Nicholas J.} and Kindler, {Hedy L.} and Kern, {Jeffrey A.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1097/JTO.0b013e318168da0a",
language = "English",
volume = "3",
pages = "417--421",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "4",

}

Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a : Results of cancer and leukemia group B 159904. / Kratzke, Robert A.; Wang, Xiaofei; Wong, Long; Kratzke, Marian G.; Green, Mark R.; Vokes, Everett E.; Vogelzang, Nicholas J.; Kindler, Hedy L.; Kern, Jeffrey A.

In: Journal of Thoracic Oncology, Vol. 3, No. 4, 01.01.2008, p. 417-421.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a

T2 - Results of cancer and leukemia group B 159904

AU - Kratzke, Robert A.

AU - Wang, Xiaofei

AU - Wong, Long

AU - Kratzke, Marian G.

AU - Green, Mark R.

AU - Vokes, Everett E.

AU - Vogelzang, Nicholas J.

AU - Kindler, Hedy L.

AU - Kern, Jeffrey A.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - INTRODUCTION: The molecular mechanisms of oncogenesis in mesothelioma involve the loss of negative regulators of cell growth including p16. Absence of expression of the p16 gene product is exhibited in virtually all mesothelioma tumors and cell lines examined to date. Loss of p16 expression has also been frequently observed in more common neoplasms such as lung cancer as well. In a wide variety of these malignancies, including lung cancer, p16 expression is known to be inactivated by hypermethylation of the first exon. This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16 via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC). METHODS: Using tissue samples from CALGB 8833 and 9031, two clinical studies which used DHAC based therapy in mesothelioma, this study tested the hypothesis that tumors possessing methylation of p16 would have a better response and survival following DHAC treatment than their nonmethylated counterparts. RESULTS: Methylation of p16 was identified in 4 of the 20 specimens. Although there was a trend towards improved survival the result was not statistically significant. CONCLUSIONS: There was no significant correlation between the presence of p16 methylation and response to DHAC therapy or overall survival.

AB - INTRODUCTION: The molecular mechanisms of oncogenesis in mesothelioma involve the loss of negative regulators of cell growth including p16. Absence of expression of the p16 gene product is exhibited in virtually all mesothelioma tumors and cell lines examined to date. Loss of p16 expression has also been frequently observed in more common neoplasms such as lung cancer as well. In a wide variety of these malignancies, including lung cancer, p16 expression is known to be inactivated by hypermethylation of the first exon. This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16 via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC). METHODS: Using tissue samples from CALGB 8833 and 9031, two clinical studies which used DHAC based therapy in mesothelioma, this study tested the hypothesis that tumors possessing methylation of p16 would have a better response and survival following DHAC treatment than their nonmethylated counterparts. RESULTS: Methylation of p16 was identified in 4 of the 20 specimens. Although there was a trend towards improved survival the result was not statistically significant. CONCLUSIONS: There was no significant correlation between the presence of p16 methylation and response to DHAC therapy or overall survival.

KW - Mesothelioma

KW - Methylation

KW - p16

UR - http://www.scopus.com/inward/record.url?scp=41749102001&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318168da0a

DO - 10.1097/JTO.0b013e318168da0a

M3 - Article

VL - 3

SP - 417

EP - 421

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 4

ER -